Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

302
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
302
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

407
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
407

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia.

Bone marrow transplantation·2025
Same author

Improved oral anticancer medication (OAM) adherence/toxicity assessment documentation: A quality improvement initiative.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2025
Same author

Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia.

European journal of haematology·2024
Same author

Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?

Leukemia·2024
Same author

Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.

Leukemia research·2024
Same author

How I treat AML incorporating the updated classifications and guidelines.

Blood·2023

Related Experiment Video

Updated: Nov 6, 2025

Gene Transfection toward Spheroid Cells on Micropatterned Culture Plates for Genetically-modified Cell Transplantation
07:40

Gene Transfection toward Spheroid Cells on Micropatterned Culture Plates for Genetically-modified Cell Transplantation

Published on: July 31, 2015

8.9K

Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit.

David O Riley1, Jenna M Schlefman2, Hans Christoph Vitzthum Von Eckstaedt V3

  • 1Department of Medicine, Division of Hematology and Oncology, University of Virginia School of Medicine, 1215 Lee Street, Charlottesville, VA, 22903, USA.

Current Hematologic Malignancy Reports
|May 12, 2021
PubMed
Summary
This summary is machine-generated.

Pegaspargase is crucial for adult acute lymphoblastic leukemia (ALL) treatment, but its toxicities require careful management. Understanding and addressing side effects like thrombosis and pancreatitis can prevent treatment discontinuation and maximize patient benefit.

Keywords:
Acute lymphoblastic leukemiaAsparaginaseHepatotoxicityInactivationPancreatitisThrombosis

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.1K
CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

3.9K

Related Experiment Videos

Last Updated: Nov 6, 2025

Gene Transfection toward Spheroid Cells on Micropatterned Culture Plates for Genetically-modified Cell Transplantation
07:40

Gene Transfection toward Spheroid Cells on Micropatterned Culture Plates for Genetically-modified Cell Transplantation

Published on: July 31, 2015

8.9K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.1K
CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

3.9K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Pegaspargase is vital in adult acute lymphoblastic leukemia (ALL) chemotherapy.
  • Its unique toxicity profile presents management challenges.

Purpose of the Study:

  • To review significant pegaspargase toxicities.
  • To provide guidance on preventing and managing these toxicities.
  • To ensure maximum clinical benefit from pegaspargase therapy.

Main Methods:

  • Review of clinically significant pegaspargase toxicities.
  • Analysis of management strategies for adverse events.
  • Discussion of implications for treatment adherence.

Main Results:

  • Key toxicities include thrombosis, hypersensitivity, inactivation, hepatotoxicity, pancreatitis, and hypertriglyceridemia.
  • Most toxicities are manageable supportively, allowing continued treatment.
  • Pancreatitis and inactivation require specific attention and may necessitate therapy cessation.

Conclusions:

  • Pegaspargase's manageable toxicity profile should not impede its use in adult ALL.
  • Effective management strategies are essential for optimal patient outcomes.
  • Further research is needed for patients intolerant to pegaspargase.